Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

AUA 2022 | Should polygenic risk scores be used to risk-stratify the use of PSA-screening in prostate cancer?

Andrew Vickers, PhD, Memorial Sloan Kettering Cancer Center, New York City, NY, discusses the limitations of using polygenic risk scores (PRSs) to risk-stratify PSA-screening. An important consideration when developing screening programmes is the ‘net benefit’ of lives saved vs. factors such as the cost of screening and overdiagnosis. For prostate cancer, an effective screening programme would need to use a marker that doesn’t just predict incidence but also predicts mortality. Dr Vickers concludes that stratifying the population and only screening those at high-risk will only be effective if the marker used is better at predicting mortality than incidence. This interview took place at the American Urological Association annual congress 2022 in New Orleans and online.

Disclosures

I receive royalties from sale of the 4Kscore, a prostate cancer test

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.